Premium
Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study
Author(s) -
Sharma Ruchika,
Woods Gary M.,
Creary Susan,
O'Brien Sarah,
Stanek Joseph,
Hor Kan,
Gallagher Christina,
Dunn Amy L.,
Kumar Riten
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27588
Subject(s) - medicine , retrospective cohort study , etiology , disease , sickle cell anemia , central venous catheter , cohort , venous thromboembolism , pediatrics , intensive care medicine , surgery , catheter , thrombosis
Venous thromboembolism (VTE) is being increasingly recognized in children with sickle cell disease (SCD). In a retrospective cohort study, we identified bilateral central venous catheter (CVC) placement as an independent risk factor for VTE. At our institution, the only indication for bilateral CVC placement in children with SCD is erythrocytapheresis. To investigate the impact of erythrocytapheresis on coagulation, we measured levels of natural anticoagulants in 11 patients with SCD on chronic erythrocytapheresis, immediately before and after apheresis. We demonstrated a statistically significant reduction in most parameters. Additional studies are needed to further investigate the exact etiology and clinical impact of this acute decrease.